


# Journey of a Liquid Biopsy

## What is a liquid biopsy based test?

Certain lung cancer patients are not good candidates for tissue biopsy as this is an invasive procedure that carries risk. Liquid biopsy offers a non-invasive alternative for clinicians to identify clinically relevant biomarkers in patients to guide treatment decisions.

A liquid biopsy test looks for cancer cells or DNA fragments (cfDNA) from a tumour that is circulating in the blood.<sup>1</sup> Obtaining blood samples is less invasive compared to traditional tissue biopsies.



## Opportunities

In NSCLC\*, EGFR (Epidermal Growth Factor Receptor) testing is not performed in


**~20%** of eligible patients

due to **unavailable or insufficient tissue**<sup>2</sup>

\*Non Small Cell Lung Cancer


Liquid biopsy can help provide results to clinicians and their patients **within 1 day**

Liquid biopsy can help **overcome complications** of a lung biopsy and is playing an increasingly important role as a companion diagnostics in cancer management



## Applications


### Now



#### Today

- Identify mutations
- Treatment decisions (e.g. NSCLC)
- Response to treatment (e.g. EGFR inhibitors)

### Future



#### Tomorrow

- Treatment decisions for many cancers
- Monitoring for recurrence
- Screening for early diagnosis

Liquid biopsy offers a non-invasive approach for personalised patient care.

References:  
 1. <https://www.cancer.gov/publications/dictionaries/cancer-terms>, accessed March 2017  
 2. 2015 European Lung Cancer Conference (ELCC): Abstract LBA2\_PR. Presented April 17, 2015